Research Assessment Seeks Evidence to Guide Treatment of MPN With COVID-19
Investigators assessed studies for evidence to guide the management of MPN in patients with COVID-19.
Myeloproliferative Neoplasms
BRCA1 and BRCA2 May Play Underappreciated Role in Patients With Familial Myeloproliferative Neoplasms
Researchers sought to determine the role of BRCA1/2 mutations in patients with MPNs.
Review of the Prognostic Role of Cytogenetics in Philadelphia-Negative Myeloproliferative Neoplasms
Researchers sought to determine the prognostic role of cytogenetics in Philadelphia-negative myeloproliferative neoplasms.
Myeloproliferative Neoplasms: How Do MPNs Affect Quality of Life?
As myeloproliferative neoplasms (MPNs) are a rare form of blood cancer, patients may not be aware of its effects. How do MPNs affect a patient’s quality of life, and what do your patients need to know?
Disease Features in Young Patients With Myeloproliferative Neoplasms
Researchers found a high incidence of thromboembolic events in young patients with myeloproliferative neoplasms, especially polycythemia vera.
Thromboses in Pediatric Patients With Myeloproliferative Neoplasms
Researchers sought to determine the occurrence of thrombotic events in a cohort of pediatric patients with myeloproliferative neoplasms.
Polycythemia Vera: A Comprehensive Approach to Management
Review highlights current approaches to risk stratification, differential diagnosis, and the optimal use of current treatment options for polycythemia vera.
Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Myeloproliferative Neoplasms: Driver Mutations Occur Decades Before Clinical Presentation
Detection of driver mutations acquired very early in life and life-long clonal expansion may predict clinical outcomes and interventions for patients with myeloproliferative neoplasms.
Mortality Rates, Diverse Causes of Death in Polycythemia Vera
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
- Loading...
Loading...
Loading... 
Loading...